Lupin Ltd announced today that it has received approval to launch Acotiamide 100 mg indigestion tablets in India from the Central Drugs Standard Control Organization.
Acotiamide is a drug to be introduced into the Indian Pharmaceutical Market which
could benefit millions of patients suffering from Dyspepsia or Indigestion, most common stomach complaints encountered in clinical practice.
Acotiamide enhances gastric accommodation and gastric emptying, the two factors which have been implicated in the cause of functional dyspepsia.
“I am sure that the approval of Acotiamide would go a long way in addressing an otherwise common but unmet medical need for a safe and effective drug for the management of dyspepsia” said, Naresh Gupta, President, Lupin Ltd.
The current market for plain Gastrointestinal prokinetics drugs is estimated to be around ₹2,640 Cr growing at 14%.
Lupin is transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.